clinical trials and expert recommendations. The harmonization of PT results is hampered by the lack of a natural primary standard. This obstacle has been circumvented by the concept of the International Normalized Ratio (INR). Prerequisite to this harmonization has been adoption by the WHO of an international reference thromboplastin preparation (13, 14 ) : each new commercial thromboplastin is calibrated against the primary WHO reference preparation. The results are used to calculate the relative sensitivity of the unknown preparation compared with the WHO standard International Sensitivity Index (ISI) (15 ) . The INR is calculated according to the formula:
ISI (15 ) . Increasing use of the INR format has led to appreciation of its limitations (5, 16 -19 ) . These include poorer accuracy and precision when insensitive (high ISI value) thromboplastins are used, incorrect assignment of an ISI value by the manufacturer, use of a reagent-instrument combination different from that used by the manufacturer, and acceptance of an incorrect PT value for the reference plasma used for calibration and quality control (20 ) . It is somewhat surprising that, despite the wide use of oral anticoagulation therapy and its laboratory monitoring, only limited information is available concerning agreement among results obtained with the various INR methods. Preliminary data from our laboratory point to the possibility that the Quick and Owren methods may produce different results (21) (22) (23) . Moreover, some of the results may be systematically biased and clinically unacceptable (24 ) . In the present study, we sought to establish how general these problems are by comparing the INR results for 150 blood samples and determining the INR values obtained with seven commercial INR methods, four Quick-and three Owren-based methods.
Materials and Methods patients and blood sampling
Hospital and health-center patients were eligible if a PT time test was requested for the monitoring of oral anticoagulation therapy. In our region, a "P-INR" test code is used for this purpose. Hence, the samples represented all possible phases of anticoagulation (before treatment, dose-adjustment phase, and steady-state phase) and not the chronic phase alone. Patients were chosen without conscious bias. All procedures were approved, in accordance with the Helsinki Declaration of 1975, by our institution's responsible ethics committee.
Blood (1.8 mL) was drawn from 150 patients into citrate coagulation tubes (Vacuette cat. no. 454322, 9NC or 454392, 9NC; Greiner Labortechnik GmbH), the great majority of them containing 0.2 mL (0.109 mol/L) of citrate solution. We received from the district health centers two or three samples in 129 mmol/L citrate tubes previously used in our laboratories. This "contamination" could not be identified, and the results are included in the final data. Sample tubes were centrifuged at 1850g for 10 min at 20°C to separate plasma. Measurements commenced within 8 h of blood collection with minimal delay between runs.
pt determination
The PT coagulation times were measured by use of a fully automated BCS coagulation analyzer (The Dade Behring Coagulation System). For the one-stage PT with the Quick method, 100 L of coagulation reagent was added to 50 L of citrated plasma. The four test reagents were as follows:
• Neoplastine CL Plus (rabbit brain thromboplastin; cat.
no 
analytical imprecision of pt determinations
We assessed the within-run imprecision of the seven PT tests, using one patient plasma sample (n ϭ 10 determinations) with an INR value in the therapeutic range, i.e., ϳ2.2 INR. The respective CVs were 2.3% for the Neoplastine CL Plus, 2.7% for the PT-Fibrinogen Recombinant, 1.1% for the PT-Fibrinogen HS Plus, 2.6% for the Dade Innovin, 1.4% for the Owren PT, 1.6% for the Nycotest PT, and 1.0% for the SPA. The third parameter, or 95% prediction interval, is the y (INR difference) range for a given x (INR average), where there is a 95% probability that the next assay y value will occur based on the fit of the present experimental data. We used STATISTICA (data analysis software system), Ver. 6 (www.statsoft.com. StatSoft, Inc., 2004) throughout.
Results
We compared the results obtained by seven different commercial INR determination methods for 150 blood samples from patients with imminent or ongoing oral anticoagulation therapy. One sample gave very discrepant results with one reagent and was rejected. The final number of patients was therefore 149. All four ISI calibrators were used for the calibration of all seven methods. The INR values obtained with the different methods were very similar around the normal plasma value, or INR ϭ 1 (Fig. 1) . In contrast, marked differences were seen at higher INR values.
The results were dependent on the calibration method used (Fig. 1) . Friedman ANOVA and Kendall concordance analysis demonstrated poor overall agreement between different methods when INR values obtained by individual calibrations (Fig. 1A) were assessed (P Ͻ0.0001; coefficient of concordance ϭ 0.458). The means, medians, and standard deviations of the results are given in detail in Table 1 Visual assessment of Fig. 1A revealed that the lack of a significant difference does not necessarily indicate similarity and that random and nonrandom variability may be present. The statistical significance of the differences in the other 17 comparisons persisted with even the most conservative statistical treatment using a Bonferroni-type correction, i.e., even after we multiplied the P values by 17, they were still Ͻ0.001. This means that all INR methods tested here gave either inconsistently or systematically different results.
None of the four calibration methods, when applied to all INR methods, essentially harmonized the results (Fig.  1, B-E) . This was also exemplified when we used Bioclin as a calibrator (Table 1 ). The maximum difference between the mean INR values obtained by two different PT methods (PT-Fibrinogen HS Plus and Neoplastine CL Plus) was 0.64 INR units.
We performed all 21 possible pairwise comparisons of the results obtained with the seven INR methods by plotting the results according to the Bland-Altman method. This strategy revealed three types of agreement problems: (a) The scatter of the difference in results obtained by the two methods to be compared increased according to the prolongation of PTs. In other words, the agreement between the two methods deteriorated toward the clinically important anticoagulation values. We observed a very large scatter ratio of the INR differences, 2.9 ( Fig. 2I) , with PT-Fibrinogen Recombinant vs the Owren PT. The absolute variation in differences is better indicated by the 95% prediction interval of the differences. In this regard, the most marked variation in agreement of results, i.e., a prediction interval of 2.9 INR units, was between PT-Fibrinogen Recombinant and Nycotest PT (Fig. 2J) . Several comparisons revealed a substantial dependence of INR difference on the mean INR. This was indicated by the slopes of the regression lines in the Bland-Altman plots. The steepest slope, 0.54, was for Nycotest PT vs SPA 50 (Fig. 2U ). All slopes differed statistically significantly from zero (P Ͻ0.001, Pearson product-moment correlation analysis). Similarly, the nonparametric Spearman rank-order correlation test demonstrated a statistically significant correlation (P Ͻ0.001) between the INR average vs INR mean.
Discussion
Harmonization of PT results and therapeutic ranges globally is an important goal. The introduction and recommendation of INR units were intended to serve this end because INR units are easy to handle by both patients and physicians and concordance of INR results worldwide would facilitate better care of individual patients. The major consideration was reliable and safe adoption of the results obtained by anticoagulation trials and of expert guidelines for treatment. The results of the present study, however, unfortunately demonstrate that the goal has not been achieved. Agreement among most of the INR methods tested here was particularly poor. Because of the wide global coverage of these reagents, our findings must be seen to refute the principle. In other words, the strategy of deriving equal INR results on the basis of the "WHO mother standard" (14, 15 ) does not work in its current form for manufacturer or for local calibrations.
The seven reagents selected all have low ISI values. The mathematical correction of INR results close to the ISI value of 1 is minimal. It is thus likely that the present study was conservative in revealing the agreement problems among PT reagents. The effect of ISI and the respective calibration, as a power function, increases with prolongation of PT times, so that even poorer agreement of INR results is likely with less sensitive reagents representing higher ISI values.
The results were in a very good agreement in patients with INR values close to 1, but increasingly poorer the first question, all available information must be taken into account. It must be noted that only a fraction of the blood components involved in the clotting reaction have been characterized. Different reagents are known to vary with respect to source of thromboplastins and other reagent components, and these have likewise not been characterized in detail. Hence, the theoretical basis of the ISI principle is itself not necessarily sound, as has been emphasized by several critics (17) (18) (19) . There are, moreover, very few, if any, published investigations in which good agreement between different INR-based PT methods has been demonstrated. In contrast, the observations of Jackson et al. (28 ) as well as our own (21-23 ) have indicated poor agreement among PT methods. We emphasize, however, that the sampling in the current study was not necessarily performed in a chronic or stable phase of anticoagulation. Hence, it remains to be determined whether the remarkable bias among many INR methods applies similarly to samples taken from patients who have been on anticoagulant therapy for different periods of time.
How are we to improve the comparability of different INR methods? One, unfortunately impractical, answer would be to adopt one single reagent globally. A compromise strategy would be to use the same secondary standard in all laboratories. This approach, however, also is impractical. The next alternative would be for all laboratories to choose the most appropriate PT determination method available. Our study demonstrates that, for the Quick PT, bias is greater and varies much more widely than for the Owren method. We did not investigate the biochemical mechanisms underlying this marked difference in the current study, but the theoretical reasons for the smaller variability of Owren PT times may well lie in the considerably smaller differences in the sample matrix (21, 29 ) . In the Owren method, exogenous coagulation factor V and fibrinogen are added to the reaction mixture, and this eliminates the effect of the internal variation of these coagulation proteins. Furthermore, the proportion of the original plasma is only 5% in the Owren PT vs 33%, or a 6.6-fold higher proportion of plasma, in the Quick reaction. The substrate concentration is a well-known determinant of the velocity of the coagulation reaction (30 ) . As shown here, the difference in INR results may of course be in equally poor agreement with longer Owren PT times. Nevertheless, the conceivably more appropriate reaction conditions and smaller INR value bias make the Owren PT principle an attractive alternative to achieve acceptable INR results for clinical practice.
In conclusion, we tested seven different INR methods and four calibrators, using 149 patient samples. Pairwise comparisons of the results demonstrated a clinically unacceptable divergence among most methods. The application of results of clinical anticoagulation trials and expert recommendations are thus by no means straightforward for clinical practice. Better approaches are needed. The Owren PT has some advantages over the Quick method, a theoretical consideration supported by the experimental data presented here.
